Camilla Pilati

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3248449/publications.pdf

Version: 2024-02-01

32	3,817	331538 21	395590 33
papers	citations	h-index	g-index

33	33	33	6848
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nature Communications, 2013, 4, 2218.	5.8	513
2	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature, 2009, 457, 200-204.	13.7	437
3	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research, 2016, 22, 4057-4066.	3.2	433
4	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nature Genetics, 2015, 47, 1187-1193.	9.4	387
5	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. Journal of Hepatology, 2012, 56, 184-191.	1.8	354
6	Molecular Classification of Hepatocellular Adenoma AssociatesÂWith Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6.	0.6	290
7	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. Cancer Cell, 2014, 25, 428-441.	7.7	240
8	Genotypeâ€phenotype correlation of CTNNB1 mutations reveals different ÃŸâ€catenin activity associated with liver tumor progression. Hepatology, 2016, 64, 2047-2061.	3.6	222
9	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. Journal of Experimental Medicine, 2011, 208, 1359-1366.	4.2	218
10	Mutational signature analysis identifies <scp>MUTYH</scp> deficiency in colorectal cancers and adrenocortical carcinomas. Journal of Pathology, 2017, 242, 10-15.	2.1	130
11	A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. Clinical Cancer Research, 2014, 20, 4499-4510.	3.2	55
12	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica, 2013, 98, 1748-1752.	1.7	50
13	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Human Pathology, 2018, 81, 157-165.	1.1	44
14	CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. Annals of Oncology, 2017, 28, 1032-1035.	0.6	43
15	Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine and Growth Factor Reviews, 2015, 26, 499-506.	3.2	42
16	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. OncoImmunology, 2013, 2, e27090.	2.1	39
17	Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis. BMC Cancer, 2019, 19, 232.	1.1	37
18	Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 939-947.	1.4	36

#	Article	IF	Citations
19	Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. Molecular Therapy, 2016, 24, 660-661.	3.7	33
20	Sulfheme formation during homocysteine S-oxygenation by catalase in cancers and neurodegenerative diseases. Nature Communications, 2016, 7, 13386.	5.8	30
21	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. Clinical Cancer Research, 2021, 27, 4768-4780.	3.2	25
22	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. EBioMedicine, 2019, 46, 94-104.	2.7	24
23	Histo-molecular oncogenesis of pancreatic cancer: From precancerous lesions to invasive ductal adenocarcinoma. World Journal of Gastrointestinal Oncology, 2018, 10, 317-327.	0.8	22
24	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. Clinical Cancer Research, 2017, 23, 1200-1212.	3.2	21
25	CD200 expression is a feature of solid pseudopapillary neoplasms of the pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 105-109.	1.4	19
26	Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. Pharmacogenomics, 2014, 15, 1043-1052.	0.6	16
27	Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. British Journal of Cancer, 2015, 113, 680-685.	2.9	11
28	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma. Pancreas, 2019, 48, 70-76.	0.5	11
29	Prognostic value of the PrP ^C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. OncoImmunology, 2021, 10, 1940674.	2.1	11
30	AAV2 and Hepatocellular Carcinoma. Human Gene Therapy, 2016, 27, 211-213.	1.4	8
31	Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. Journal of Gastrointestinal Oncology, 2018, 9, E23-E27.	0.6	7
32	Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy. Cancer Research, 2021, 81, 2730-2744.	0.4	4